Figure 1.

Proportion of patients receiving anti‐programmed death protein 1 (anti‐PD1) treatment, January 1, 2013, to August 31, 2016. Anti‐PD1 treatment was assessed across categories of race using chi‐square tests, with p values listed by cancer type. Because of small sample sizes (<5 patients) among those with melanoma, we tested black patients and Asian patients with melanoma in the “Other” race group, which lowers the risk of patient identification.

Abbreviations: NSCLC, non‐small cell lung cancer; RCC, renal cell carcinoma.